I would imagine Southeastern Pennsylvania Transportation Authority would be interested in the Hemopurifier results in India and the testing just approved in the U.S. since SPTA is suing Gilead Sciences for the high price of Sovaldi.
While doing some research on Dr Michael Mawanda, I came across a website for New Vision in Uganda. They had a Feedback tab so I sent the following:
"In October Dr Michael Mawanda of Uganda was treated in Frankfurt, Germany for having contacted a severe case of Ebola while attending patients in Sierra Leone. In conjunction with his treatment a Hemopurifier from Aethlon Medical was used to remove the Ebola virus from his blood. The procedure took 6.5 hours and he showed remarkable recovery after 16 hours and he has been discharged. Why haven't there been follow-up on this apparent life saving device for use in the four African countries for at least treatment for health aid workers?"
Very shortly I received this reply:
"Thanks for your valuable feedback.Your suggestion is very important for us." If this was just an auto answer, how did they know I had a suggestion?
Hard to believe this company is a scam. Here's an announcement on 12/5:
Aethon and BD Announce Collaboration to Develop Integrated Medication Management Solution
Tony Melanson - Dec 5, 2014
(PITTSBURGH, PA – December 5, 2014) ─ Aethon, Inc. and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a collaboration to integrate their solutions to provide hospital pharmacies with a comprehensive intravenous medication preparation and delivery tracking solution. With a pilot project already underway, the integrated solution will combine BD’s leading-edge BD Cato™ IV Workflow product with Aethon’s MedEx medication delivery tracking system.
You can just google Aethon Medical - the article is under News & Events - Aethlon. The announcement isn't relating to the Hemopurifier but it indicates a company that is moving ahead on more than one front.
What you describe happens a lot. But Citicorp did it when they were crushed in the mortgage debacle. Otherwise institutions would be forced to sell their stock hovering around $2 - 3. They need to get their stock above $5. I think they did a 1:10 split. On the other hand maybe AEMD will get bought out before they need to get off the pink sheets.
how much did they cover before the end of the day? There are be lots of shorting during the session and covering too.
If it is a single use device, the cost could be very cheap.
Awful lot of high powered MDs to just say "the vaccine is safe". Looks like a mad scramble to get aboard the NWBO ship before it launches.
The shorts that want out can start by raising the bid - it's easy to get out - only a matter of price.
There has been no communication regarding what Northwest Bio will receive in payment for DCVas-L. Granted the German hospitals will be reimbursed for the cost, but that cost won't be determined until the hospitals get the necessary reimbursement agreement.
Certainly the lack of communication on on the clinical trials from the company AND outside professional and the lack of the German reimbursement agreement coupled with all the negative speculation and "analysis" are taking a toll on the longs. Low volume IMO means that one by one longs are losing confidence. If the company announced bad news, there would be an avalanche of selling. BUT on the other hand, why would an institution that a few months ago invested $15+ million in stock and just this week buys $11.5 million more shares if disaster lays ahead?
Just a hunch, but when bad news (like the SA article on Wednesday) doesn't make a stock tank, investors often conclude the selling is over and jump on. One of my biggest shorts (15,000 shares) covered Wednesday. IMO some of these shorts know the MM book and can tell when a trend is over.
Am down to about 10% of my stock loan that's lent out to NWBO shorts. IMO they are covering rather than chasing cheaper borrowing. Interest rate is 12% vs the high of 34% a few weeks ago.
Hard to recon Biotech Hawk's numbers with LP's London presentation that the manufacturing process has undergone 10 years of development and the process has been refined to make a 3 - 5 years dosage in 8 days for each patient and that the process has been approved by UK, German, and US regulators. She talks about doing it in a practical approach so that the treatment can be widely applied. There's too much of a disconnect here to take Biotech Hawk's analysis as "very factual".
thanks for the reference. Noticed that MF expects "negligible" revenue from the German approval of DC-Vax L on the hospital exemption. I imagine Linda is getting beaten down on what they will be paid.